文献速递心境障碍物质与行为成瘾

致幻剂诱发的轻躁狂与躁狂:系统综述与荟萃分析

Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.
PubMed 文献 · Mol Psychiatry · 2026-05-29

该研究系统检索了截至2026年1月26日的人体研究,评估血清素能致幻剂或MDMA暴露后轻躁狂/躁狂症状及向双相障碍转换的风险。致幻剂相关心境症状发生率从对照试验中的5.8%到双相障碍自然研究中的30%不等,注册队列中后续双相转换率为4%(95%CI 2-8%)。

要点

  • 致幻剂相关轻躁狂/躁狂在易感个体中呈低但具临床意义的相对风险。
  • 注册队列中后续双相障碍转换率为4%(95%CI 2-8%),无致幻剂特异性信号。
  • 躁狂症状通常为急性且自限性,对照临床环境中相对安全。

核心结论

  • 血清素能致幻剂在易感个体中诱发短暂心境相关症状的相对风险低但具临床意义,在对照临床环境中相对安全。

主要发现

  • 致幻剂相关烦躁/欣快、轻躁狂或躁狂的发生率从迷幻剂辅助心理治疗重性抑郁障碍对照试验中的5.8%到双相障碍个体自然研究中的30%不等。
  • 注册队列中后续向双相障碍转换的患病率为4%(95%CI 2-8%;N=7478;I²=32.1%),几乎没有致幻剂特异性信号的证据。
  • 观察性研究识别出双相I型障碍、家族易感性、多物质使用及无监督或非法使用者的风险更高。

关键数值与推荐

  • 纳入研究的设计类型包括随机与非随机临床研究、注册队列、横断面调查和纵向观察研究。
  • 偏倚风险评估使用ROBINS-I、ROB2或NIH工具。

临床怎么用

  • 在对照临床环境中使用血清素能致幻剂时,应评估个体的双相谱系易感性、家族史及物质使用情况。
  • 对双相I型障碍或家族易感性个体,需警惕致幻剂暴露后急性自限性躁狂症状的出现。

局限性

  • 长期结局和重复暴露研究不足,需严谨的纵向研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serotonergic psychedelics are increasingly investigated as treatments for affective disorders. Concerns persist regarding their potential to induce hypomania or mania, particularly in individuals with bipolar spectrum vulnerability. Whether these substances precipitate transient mood switches or contribute to persistent bipolar illness or diagnostic transition remains unclear. We conducted a systematic review of human studies examining manic or hypomanic symptoms following exposure to serotonergic psychedelics (psilocybin, LSD, mescaline, DMT/ayahuasca) or MDMA (CRD420251160656). Databases and trial registries were searched through January 26, 2026. Eligible designs included randomized and non-randomized clinical studies, registry-based cohorts, cross-sectional surveys, and longitudinal observational studies. Outcomes included dysphoria/euphoria, manic or hypomanic symptoms and transition to bipolar disorder. Risk of bias was assessed using ROBINS-I, ROB2 or NIH tools. Twenty-three studies met inclusion criteria, four contributing to meta-analysis. Rates of psychedelic-associated dysphoria/euphoria, hypomania or mania ranged from 5.8% in controlled trials of psilocybin-assisted psychotherapy for major depressive disorders to 30% in naturalistic studies of individuals with bipolar disorder. When present, manic symptoms were typically acute and self-limited. Observational studies identified higher risks among individuals with bipolar I disorder, familial vulnerability, polysubstance use, and unsupervised or illegal use. Registry-based cohorts examining diagnostic transitions showed a prevalence of subsequent transition to bipolar disorder of 4% (95% CI 2-8%; N = 7478; I² = 32.1%), with little evidence for a hallucinogen-specific signal. Overall, serotonergic psychedelics appear to pose a low but clinically meaningful relative risk of transient mood-related symptoms in susceptible individuals while remaining relatively safe in controlled clinical settings. Long-term outcomes and repeated exposure remain insufficiently studied, underscoring the need for rigorous longitudinal research.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Eskinazi M, Nasserdine R, Cusin RM, et al. Psychedelic-induced hypomania and mania: a systematic review and meta-analysis. Mol Psychiatry. 2026. PMID: 42215638. doi:10.1038/s41380-026-03657-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。